Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy

AIDS

Volumn 13, Issue 13, 1999, Pages 1705-1709

  Pellegrin, Isabelle ^c   Izopet, Jacques ^a   Reynes, Jacques ^b   Denayrolles, Muriel ^d   Montes, Brigitte ^b   Pellegrin, Jean Luc ^d   Massip, Patrice ^a   Puel, Jacqueline ^a   Fleury, Hervé ^d   Segondy, Michel ^b   Denisi, R ^d   Dupon, M ^d   Lacut, J Y ^d   Leng, B ^d   Ragnaud, J M ^d   Bicart Sec, A ^d   Bonnet, E ^d   Marchou, B ^d   Obadia, M ^d   Delmas, B ^d   Fabre, J ^d   Favier, C ^d   Leclercq, C ^d   more..

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c HÔPITAL PELLEGRIN   (France)

^d NONE

Author keywords

HIV 1; Lamivudine; Resistance mutation; Reverse transcriptase; Stavudine; Zidovudine

Indexed keywords

DIDANOSINE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DIDANOSINE; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; VIRAL LOAD; ZIDOVUDINE;

EID: 0033381530     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199909100-00014     Document Type: Article

References (16)

1. Kellam P, Boucher CAB, Tijnagel JM, Larder BA. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol 1994, 75:341-351.
2. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
3. Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother 1997, 41:757-762.
4. Fitzgibbon JE, Howell RM, Haberzettl CA, Sperber SJ, Gocke DJ, Dubin DT. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′-3′ dideoxycytidine. Antimicrob Agents Chemother 1992, 36:153-157.
5. Shirasaka T, Kavlick MF, Ueno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995, 92:2398-2402.
6. Deminie CA, Bechtold CM, Riccardi K, et al. Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy. AIDS 1998, 12:110-112.
7. Soriano V, Dietrich U, Villalba N, et al. Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy [letter]. AIDS 1997, 11:696-697.
8. Lacey SF, Larder BA. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′, 3′ didehydro-3′-deoxythymidine in cell culture. Antimicrob Agents Chemother 1994, 38:1428-1432.
9. Gu Z, Gao Q, Fang H, Parniak MA, Brenner BG, Wainberg MA. Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene. Leukemia 1994, 8 (suppl 1):S166-S169.
10. Whitcomb JM, Limoli K, Wrin T, et al. Phenotypic and genotypic analysis of stavudine-resistant isolates of HIV-1. Second International Workshop on HIV Drug Resistance, Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstract 17].
11. Reynes J, Denisi R, Bicart-Sée A, et al. STADI Pilot Study: once daily administration of didanosine (ddl) in combination with stavudine (d4T) in antiretroviral naive patients. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September-October 1997 [abstract 1128A].
12. Segondy M, Izopet J, Pellegrin I, et al. Comparison of the QUANTIPLEX HIV-1 RNA 2.0 assay with the AMPLICOR HIV-1 MONITOR 1.0 assay for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma of patients receiving stavudine-didanosine combination therapy. J Clin Microbiol 1998, 36:3392-3395.
13. Schmit JC, Cogniaux J, Hermans P, et al. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis 1996, 174:962-968.
14. Coakley E, Gillis J, Hammer S. Mutations in the reverse transcriptase (RT) coding region of HIV-1 isolates derived from individuals treated with didanosine and stavudine in combination. Second International Workshop on HIV Drug Resistance, Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstract 96].
15. Lin PF, Samanta H, Rose RE, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994, 170:1157-1164.
16. Bloor S, Hertogs K, Desmer RL, Pauwels R, Larder BA. Virological basis for HIV-1 resistance to stavudine investigated by analysis of clinical samples. Second International Workshop on HIV Drug Resistance. Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstract 15].